688076 ST诺泰生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,139,6548.72%1,942,7991,624,8021,033,548651,292
减:营业总成本784,16513.57%1,479,6041,132,859827,280547,836
    其中:营业成本461,60144.70%725,753525,057403,395276,322
               财务费用51,781172.01%57,81318,44111,589(164)
               资产减值损失(43,495)79.94%(84,325)(36,426)(28,893)(25,642)
公允价值变动收益6,479-715.36%1,492(2,792)258(1,965)
投资收益1,46631.27%2,0261,0682,90419,965
    其中:对联营企业和合营企业的投资收益------------
营业利润293,869-13.41%408,638448,218189,666123,602
利润总额238,905-29.69%360,490438,504173,127121,908
减:所得税费用29,254-21.79%35,08538,6867,674200
净利润209,651-30.66%325,405399,818165,453121,708
减:非控股权益(5,399)-29.75%(7,013)(4,572)2,517(6,336)
股东净利润215,050-30.64%332,419404,390162,936128,044

市场价值指针
每股收益 (元) *0.680-31.31%1.0601.3400.7600.600
每股派息 (元) *----0.3500.9000.4000.200
每股净资产 (元) *9.7803.97%9.44611.7879.5198.960
审计意见 #--标准无保留意见带有强调事项段的无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容